Crinetics Pharmaceuticals, Inc. announced that the late-breaking abstracts accepted for presentation at the Endocrine Society?s annual meeting (ENDO 2024) were released earlier than the previously announced embargoed date. The abstract for the Phase 2, open-label study of atumelnant (CRN04894), in Congenital Adrenal Hyperplasia contained summary data for four subjects at the time of submission. The company plans to present additional data from a total of six subjects in cohort 1 and additional subjects in cohort 2 at ENDO 2024.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
45.58 USD | +3.10% | +0.55% | +28.11% |
Jun. 04 | Oppenheimer Raises Price Target on Crinetics Pharmaceuticals to $74 From $55, Maintains Outperform Rating | MT |
Jun. 03 | Transcript : Crinetics Pharmaceuticals, Inc. - Special Call |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+28.11% | 3.59B | |
+34.14% | 51.12B | |
-6.54% | 39.4B | |
+34.92% | 38.48B | |
-12.11% | 26.22B | |
+12.62% | 26.36B | |
-13.43% | 20.96B | |
+43.73% | 14.02B | |
+31.81% | 12.49B | |
-4.54% | 11.61B |
- Stock Market
- Equities
- CRNX Stock
- News Crinetics Pharmaceuticals, Inc.
- Crinetics Pharmaceuticals Announces Early Release of ENDO 2024 Late-Breaking Abstracts